Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-111 and Paclitaxel in Recurrent Platinum-Resistant Müllerian Cancer
NCT01711970Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Nov 2012
- Primary completion
- May 2017
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of ofranergene obadenovec in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), uterine papillary serous carcinoma (UPSC), malignant mixed Mullerian tumor (MMMT), sponsored by VBL Therapeutics. Started Nov 2012; status: completed.
02
Drugs
ofranergene obadenovec
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)uterine papillary serous carcinoma (UPSC)malignant mixed Mullerian tumor (MMMT)
Beyond the preview
Go deeper on NCT01711970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01711970.